Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


O'Neill: Pharma Is Intrigued, Irritated But Respects The UK AMR Review

This article was originally published in Scrip

Executive Summary

Lord Jim O'Neill – ex-chair of Goldman Sachs Asset Management and the man appointed by UK Prime Minister David Cameron to launch and chair a review into the crisis of antibiotic resistance – spoke to Scrip at the recent BioInfect conference about what will happen when the Review of Antimicrobial Resistance (AMR) reaches its conclusion in summer 2016, pharma's reaction to the review so far, and how China is joining the game.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts